Take a look at this month’s industry headlines including news on Sanofi’s Dengvaxia® vaccine from the USA and the Philippines, clinical trial results for RSV vaccines and HIV injectables and new acquisitions for Merck.
Browsing: Emerging Disease > Dengue
A review of Venezuela’s current crisis has given cause for concern, highlighting the increased rate of re-emergence and spread of vector-borne diseases such as malaria, Chagas disease, dengue and Zika virus.
Take a look at this month’s industry headlines including an FDA approval for a vaccine protecting against six diseases, positive clinical trial results for bacteraemia and dengue vaccines and new funding for CRSIPR-based antimicrobials.
The US FDA has granted priority review for Sanofi Pasteur’s dengue vaccine, Dengvaxia®, despite its controversial past.
The first citywide deployment of Wolbachia has proved successful, with no dengue cases reported since Wolbachia became established.
New findings suggest that biogenesis of small regulatory fragments from tRNA can have wide ranging effects on key aspects of Aedes aegypti vector biology.
New research has suggested that mosquitoes are more likely to transmit dengue virus in warmer weather, indicating climate patterns as an early warning system for outbreaks.
Researchers have demonstrated that mice previously infected with dengue have protection against Zika virus that appears to be conferred by cytotoxic T cells.
Blood samples from US athletes and staff who travelled to Rio de Janeiro, Brazil, for the 2016 Summer Games were not infected with Zika virus but tested positive for other viral infections, including West Nile Virus, dengue and chikungunya.